Rocket Pharmaceuticals Inc (RCKT) — Titan Protect Analysis

RCKT

Rocket Pharmaceuticals Inc

Healthcare · ·

$2.75

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$316M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-2.49

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-64.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$10.00

+264% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 11 analysts covering this stock

About Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogeni

https://www.rocketpharma.com

Country: United States Employees: 202 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.656

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0794

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.711

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-64.7%

Historical annualised return based on price data

Max Drawdown

-91.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

237

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.52

Less volatile than the market — more defensive

52W High

$5.45

50% below the year high

52W Low

$2.40

15% above the year low

Avg Volume

3,239,392

Average daily shares traded — higher means easier to buy and sell

Short Ratio

10.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.87

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

10.40

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-98,859,872

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-209,383,008

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$16.00

Target Median

$10.00

Target Low

$3.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go